Galapagos (Euronext & NASDAQ: GLPG) and Gilead Sciences, Inc. received the Top Biopharmaceutical Licensing Deal award at the 2016 Allicense Deals of the Year event. Goodwin Procter represented Galapagos in the award winning deal in which Galapagos entered into a strategic collaboration with Gilead Sciences valued up to $2 billion for the development and commercialization of the JAK1-selective inhibitor filgotinib for inflammatory indications. The deal included a $300 million upfront license fee and a $425 million equity investment, one of the largest combined upfront payments in recent years.
Goodwin represented three of the five finalists for 2015 Licensing Deal of the Year and one of the finalists for M&A Deal of the Year. In addition to Galapagos, clients Foundation Medicine, CRISPR Therapeutics and Voyager Therapeutics were recognized.
Representing Goodwin at the event, Life Sciences partner Chris Denn participated in a panel discussion titled, “Strategies Supporting Breakthrough Innovations.” The 19th annual forum examined the many facets of the evolving relationship among biotech, pharma, VCs, academia and payers.
For more information on Allicense, please visit the conference website.